Sunitinib Induced Hypocalcemia and its Potential Role in the Treatment of Refractory Hypercalcemia
Journal Title: Open Access Journal of Endocrinology - Year 2017, Vol 1, Issue 1
Abstract
Background: Sunitinib, an oral multi-targeted tyrosine kinase inhibitor has been approved for the treatment of advanced pancreatic neuroendocrine neoplasms (pNENs). Aim: To describe a series of 12 patients with pNENs on sunitinib who developed hypocalcemia. Patients and Methods: Three patients developed hypocalcemia, grade 4, 1 and 2 respectively. Results: A 58-year-old man with a stage IV, grade 2, initially non-functioning pNEN (NFpNEN), developed disease progression with concomitant hypersecretion of parathyroid hormone related-peptide (PTHrP) and uncontrolled hypercalcemia. After one month of sunitinib treatment, grade 4 hypocalcemia (<6mg/dl) developed. Following treatment reinstitution at a lower dose, hypercalcemia became easily controlled. Another two patients with NFpNEN treated with sunitinib developed a grade 1 (8.2mg/dl) non-symptomatic and a grade 2 (7.2mg/dl) symptomatic hypocalcemia, both nine months after sunitinib was initiated. Conclusions: Sunitinib-induced hypocalcemia may be a common side-effect that could be of therapeutic significance in patients with pNEN and refractory PTHrP-related hypercalcemia.
Authors and Affiliations
Krystallenia I Alexandraki
Keywords
Related Articles
- EP ID EP448448
- DOI 10.23880/oaje-16000105
- Views 127
- Downloads 0
Papillary Carcinoma in Thyroglossal Duct Cyst
Objective: To report four cases of Papillary carcinoma on a Thyroglossal Duct Cyst and discuss their diagnosis and management. Method : Retrospective analysis of medical records from patients diagnosed and treated with...
Unusual Association of Two Germline Rearrangements in CDC73/HRPT2 Gene: Complexity of Clinical Counseling in the Age of Genomic Medicine
Background: Primary hyperparathyroidism is a phenotype shared by several hereditary endocrine and non-endocrine cancer predisposition syndromes caused by heterozygous germline mutations deactivating tumor suppressor gene...
Pioglitazone: An Ongoing Misery in the Developing Countries to Which I can’t be Pragmatic!
In 2014, I've published an article warning against the widespread usage of pioglitazone in the developing countries though it has been banned or heavily restricted in all developed countries due to its proved causation w...
An Update on Etiopathogenesis and Management of Type 1 Diabetes Mellitus
The incidence of type 1 diabetes mellitus (T1DM) is increasing at a massive pace globally. It results possibly from a genetic susceptibility and exposure to an environmental trigger. What is important is to use guideline...
Diabetes, Cinnamon and Green tea
Diabetes is a metabolic disease with many important complications. Recently role of herbal medicine in combination with chemicals is under consideration, especially because of few adverse effect of these medications, the...